

10/535000

JC20 Rec'd PCT/PTO 16 MAY 2005

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Serial No. : (U.S. National Phase Appln.
based on PCT/JP03/14559)

Applicants : Masakazu HATANO et al.

Filed : Concomitantly Herewith

For : THERAPEUTIC AGENT FOR
GLAUCOMA COMPRISING Rho
KINASE INHIBITOR AND
 β -BLOCKER

Docket No. : 05318/HG

Customer No.: 01933

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

MAIL STOP PCT

S I R :

Submitted herewith is a copy of the English-language
International Search Report PCT/ISA/210 (5 pages) issued in
International application No. PCT/03/14559, on which the present
U.S. national phase application is based.

Copies of the references cited in the International Search
Report have been supplied by WIPO to the USPTO. Therefore,
copies of the cited references in the International Search Report
should be on file in the United States, in accordance with
current U.S. practice.

Express Mail Mailing Label

No.: EV 626 819 641 US

Date of Deposit: MAY 16, 2005

I hereby certify that this paper is
being deposited with the United States
Postal Service "Express Mail Post
Office to Addressee" service under
37 CFR 1.10 with sufficient postage
on the date indicated above and is
addressed to:

MAIL STOP PCT

Commissioner for Patents,

P.O. Box 1450

Alexandria, VA 22313-1450



Dorothy DeFrancesco

In the event that this Paper is late
filed, and the necessary petition
for extension of time is not filed
concurrently herewith, please consider
this as a Petition for the requisite
extension of time, and to the extent
not tendered by check attached hereto,
authorization to charge the extension
fee, or any other fee required in
connection with this Paper to
Account No. 06-1378.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./

JC20 Rec'd PCT/PTO 16 MAY 2005

Attached hereto are Forms PTO/SB/08A and PTO/SB/08B, listing the particulars of the references cited in the International Search Report. As mentioned above, copies of the references should already be in the U.S. file, supplied by WIPO.

It is respectfully requested that the Examiner return initialed copies of the attached Forms PTO/SB/08A and PTO/SB/08B to confirm that the publications supplied by WIPO and listed therein have been considered and made of record.

Respectfully submitted,



RICHARD S. BARTH
REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN & CHICK, P.C.
767 THIRD AVENUE - 25TH FLOOR
NEW YORK, NEW YORK 10017-2023
Tel. Nos. (212) 319-4900
(212) 319-4551/Ext. 219
Fax No. (212) 319-5101
E-Mail Address: BARTH@FHGC-LAW.COM
RSB/ddf

Encs.: Forms PTO/SB/08A and PBO/SB/08B

Please type a plus sign ☐ inside this box →

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | | | |
|---|---|----|---|------------------------|---|
| Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/535000 (U.S. National Phase Appl. based on PCT/JP05/14559) |
| | | | | Filed | Concomitantly Herewith |
| | | | | First Named Inventor | Masakazu HATANO |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet | 1 | of | 2 | Attorney Docket Number | 05318/HG |

U.S. PATENT DOCUMENTS

| Exam. Inits* | Cite No ¹ | Document Number | Kind Code ² | Name of Patentee or Applicant | Publication Date MM-DD-YYYY | Relevant Portion |
|-----------------|-------------------------|-----------------|---------------------------|----------------------------------|--------------------------------|---------------------|
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Exam Inits* | Cite No ¹ | Offc ³ | Document Number ⁴ | Kind Code ⁵ | Name of Patentee or Applicant | Publication Date MM-DD-YYYY | Relevant Portion | T ⁶ |
|-----------------------|-------------------------|-------------------|------------------------------|---------------------------|---|--------------------------------|---------------------|----------------|
| | | EP | 1034793 | A1 | Senju Pharmaceu- ticals Co., Ltd. | 09-13-2000 | | |
| | | EP | 956865 | A1 | Yoshitomi Pharmaceutical Industries, Ltd. | 11-17-1999 | | |
| | | EP | 286903 | A1 | The Trustees of Colombia | 10-19-1988 | | |
| | | WO | 97/23222 | A1 | Alcon Laboratories, Inc. | 07-03-1997 | | |
| | | WO | 02/38158 | A1 | Pharmacia AB | 05-16-2002 | | |
| | | WO | 93/16701 | A2 | Alcon Laboratories, Inc. | 09-02-1993 | | |
| | | WO | 03/049745 | A1 | Pharmacia Corp. | 06-19-2003 | | |
| Examiner Signature | | /Gigi Huang/ | | | Date Considered | 05/12/2009 | | |

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.

DATE MAILED: MAY 16, 2005

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./

Please type a plus sign inside this box →



PTO/SB/08B (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | | | |
|---|-----------------------|---|-----------------|------------------------|---|
| Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | (U.S. PATENT OFFICE LABEL BASED ON PCT/JP03/14559) 10/535000 |
| | | | | Filing Date | CONCOMITANTLY HEREWITH |
| | | | | First Named Inventor | Masakazu HATANO |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet | 2 | of | 2 | Attorney Docket Number | 05318/HG |
| OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS | | | | | |
| Examiner Initials ¹ | Cite No. ¹ | Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published | | | T ² |
| | | <p>UEHARA, M. et al., "Calcium Sensitization of Smooth Muscle Mediated by a Rho-Associated Protein Kinase in Hypertension," <u>Nature</u>, (1997), <u>389</u>, pp. 990 to 994.</p> <p>Mariko ASahi et al., "Ryokunaisho to Ryokunaisho Chiryo Yakuzai (Fukuyaki Shido Manual II, Dai 10 Kai)," <u>The Pharmaceuticals Monthly</u>, (1996), <u>38(9)</u>, pp. 2311 to 2331.</p> <p>Kunitaru SHIRATO, "I. Ryokunaisho no Yakubutsu Ryoho 1. Gairon" (Chiryoyaku no Sentaku o Dou Kangaerunoka)," <u>Ganka</u>, (2002), <u>44(11)</u>, pp. 1443 to 1448.</p> <p>Tatsuro FUKUCHI, "I. Ryokunaisho no Yakubutsu Ryoho 2. Ryokunaisho Chiryoyaku C. Kokan Shinkei Sogaiyaku β Shadanyaku," <u>Ganka</u>, (2002), <u>44(11)</u>, pp. 1458 to 1463.</p> <p>Ikuo HIGASHI et al., "Genpatsu Kaihokaku Ryokunaisho oyobi Kogan'atsusho ni Taisuru Ensan Bunazosin Tengan'eki to Maleic Acid Timolol Tengan'eki tono Heiyo Koka no Kento," <u>The Journal of the Eye</u>, (2002), <u>19(2)</u>, pp. 261 to 266.</p> <p>Yuichiro OTAKE et al., "Betaxolol to unoprostone Heiyo Ryoho no Yukosei to Anzensei," <u>The Journal of the Eye</u>, (2000), <u>17(5)</u>, pp. 687 to 690.</p> <p>Hideki TOKUSHIGE, "ROCK Sogaiyaku to Ryokunaisho," <u>BIO Clinica</u>, (2002), <u>17(13)</u>, pp. 1191 to 1194.</p> <p>HOYNG, P.F.J. et al., "Pharmacological Therapy for Glaucoma," <u>A Review of Drugs</u>, (2000), <u>59(3)</u>, pp. 411 to 434.</p> | | | |
| Examiner Signature | /Gigi Huang/ | | Date Considered | 05/12/2009 | |

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: MAY 16, 2005

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./